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Abstract: The ongoing pandemic caused by the novel coronavirus has been the greatest global
health crisis since the Spanish flu pandemic of 1918. Thus far, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in over 1 million deaths, and there is no cure or vaccine
to date. The recently solved crystal structure of the SARS-CoV-2 main protease has been a major
focus for drug-discovery efforts. Here, we present a fragment-guided approach using ZINCPharmer,
where 17 active fragments known to bind to the catalytic centre of the SARS-CoV-2 main protease
(SARS-CoV-2 Mpro) were used as pharmacophore queries to search the ZINC databases of natural
compounds and natural derivatives. This search yielded 134 hits that were then subjected to multiple
rounds of in silico analyses, including blind and focused docking against the 3D structure of the
main protease. We scrutinised the poses, scores, and protein–ligand interactions of 15 hits and
selected 7. The scaffolds of the seven hits were structurally distinct from known inhibitor scaffolds,
thus indicating scaffold novelty. Our work presents several novel scaffolds as potential candidates for
experimental validation against SARS-CoV-2 Mpro.
Keywords: coronavirus; COVID-19; SARS-CoV-2 Mpro; main protease; fragment-guided; drug
discovery; pharmacophore; molecular docking; natural products; in silico
1. Introduction
Since the sudden outbreak of novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)
in Wuhan, China in December 2019 [1,2], the resulting pandemic has seriously challenged global
healthcare systems and caused more than 1 million deaths (as of 30 September 2020) [3]. As cases
have reached a global scale, the disease has become a major disruption to people’s daily lives and the
economy [4]. Coronavirus disease 2019 (COVID-19) can result in pneumonia and respiratory failure
that can be fatal [5], especially in the presence of other comorbidity factors. Despite ongoing efforts by
several academic and industrial groups towards developing vaccines against SARS-CoV-2 [6], we are
yet to have any vaccine approved by the Food and Drug Administration (FDA).
During the life cycle of SARS-CoV-2, two large polyproteins are translated and subsequently
cleaved by two viral proteases, main protease SARS-CoV-2 3CL Mpro (more simply, SARS-CoV-2 Mpro)
and a papain-like protease (PLpro) [7]. The dependence of the virus on Mpro, and given that there
are no similar human proteases, make this protein a promising drug target [8–10]. SARS-CoV-2 Mpro
consists of three domains. Domains I and II comprise β-barrels forming a chymotrypsin structure and
harbouring catalytic dyad histidine 41 (His41), and cysteine 145 (Cys145) [11]. Domain III consists of
α-helices (Figure 1A) [12]. For its catalytic activity, Mpro needs to dimerise, forming contacts with both
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the N- and C-terminal domains of the other protomer [13]. SARS-CoV-2 Mpro shows 96% sequence
similarity with SARS-CoV-1 Mpro, and the root-mean-square deviation (RMSD) between the two free
enzyme structures is 0.53 Å for all Cα positions [8]. The strong sequence and structural similarity
suggest that Mpro inhibitors developed for SARS-CoV-1 could also be effective against SARS-CoV-2,
although none of these inhibitors is an approved treatment so far.
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Figure 1. Representative top-ranked poses of noncovalent inhibitor X77 from multiple docking programs
(cyan sticks) and original cocrystallised pose of X77 (pink sticks) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) main protease (M ro) (Protein Data Bank (PDB) ID: 6W63) with
root-mean-square-deviation (RMSD) values. Catalytic residues, histidine 41 (His41), and cysteine 145
(Cys145) highlighted in gold. (A) Cartoon and surface representation of SARS-CoV-2 pro crystal
structure (PDB ID: 6W63) with three domains labelled (Domain I: green; Domain II: blue; Domain III:
purple). Zoom in shows AutoDock Vina result; (B) SwissDock result; (C) GOLD result; (D) AutoDock
4.2 result; (E) 2D structure of X77.
Dr g-discovery effo ts against SARS-CoV-1 Mpro have primarily involved finding peptidic
and small-molecule inhibitors targeting the active site [12,14]. Peptidic inhibitors contain chemical
warhead groups, such as Michael acceptors, to form a covalent bond with a specific cysteine residue
(Cys145) within the active site [12]. The peptidic inhibitor, called N3, (half-maximal inhibitory
concentration (IC50) = 16.77 µM) was the first to be cocrystallised with SARS-CoV-2 Mpro [14].
Several other peptidic and nonpeptidic covalent inhibitors have since been described [15], although
none has been approved as a cure for COVID-19 to date. On the other hand, noncovalently interacting
small molecules may produce fewer off-target side effects and toxicity [16]; therefore, our work focuses
on these. The most potent noncovalent inhibitor of SARS-CoV-1 Mpro so far is ML188 (antiviral
IC50 = 12.9 µM) [7,16,17], and it has also been suggested as a broad-spectrum inhibitor of coronavirus
Mpros [18]. To date, there is only one SARS-CoV-2 Mpro structure (Protein Data Bank (PDB) ID: 6W63)
with a cocrystallised noncovalent inhibitor (X77) [19]. Interestingly, X77 is similar in structure to potent
noncovalent SARS-CoV-1 Mpro inhibitor ML188.
Given the urgency for developing effective drugs against COVID-19, Diamond Light Source,
UK (www.diamond.ac.uk) performed a crystallographic fragment screening campaign (XChem
fragment screen) [20] against SARS-CoV-2 Mpro. Of these fragments, 23 were found to be noncovalently
bound to the active site of SARS-CoV-2 Mpro, 17 of which bound with high confidence. On the basis
of these noncovalently bound fragments, our study aimed to identify novel scaffolds from natural
products and derivatives against the active site of SARS-CoV-2 Mpro. In total, 134 natural products and
their derivatives were obtained through a ZINCPharmer [21] pharmacophore search and subjected
to multiple rounds of molecular docking against SARS-CoV-2 Mpro to evaluate avidity for binding
in silico. Docking scores and ligand–protein interactions were compared to those of known noncovalent
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inhibitor X77. This in silico fragment-guided approach eventually resulted in the identification of
seven novel chemical scaffolds that could be taken further to in vitro testing against SARS-CoV-2 Mpro.
2. Results
2.1. Identification of Initial Hits through Fragment-Derived Pharmacophore-Based Screening
Virtual screening in ZINCPharmer with pharmacophore queries from the 17 fragments known
to noncovalently bind to the active centre of SARS-CoV-2 Mpro [20] led to the identification of 134
scaffolds belonging to ZINC natural products and their derivative subset. The ZINC library was used
as it is a rich source of diverse and often bioactive chemical scaffolds that are commercially available.
The 134 obtained scaffolds were later subjected to blind and focused docking against the Mpro structure.
2.2. Docking-Protocol Validations
Before docking the 134 hits from the ZINCPharmer-based screening, we sought out to evaluate
the accuracy and reproducibility of our docking protocol by performing a validation or self-docking
exercise with AutoDock Vina [22], AutoDock 4.2 [23,24], SwissDock [25], and GOLD [26]. For this,
known inhibitor X77 was blindly (pseudoblindly for GOLD) docked against Mpro, and poses were
ranked on the basis of the default scoring functions of these algorithms. As shown in Figure 1,
AutoDock Vina, in blind docking mode with exhaustiveness of 24, could almost retrieve the original
pose of X77, unlike AutoDock 4.2, GOLD, or SwissDock. The docked pose of AutoDock Vina was very
closely superimposed onto the original pose within the active site of Mpro with an RMSD of ~0.9 Å,
which was well within the acceptable range (≤2 Å) for successful validation of self-docking [27].
Moreover, docked poses and relevant scores (∆G = −8.52 kcal/mol, n = 5) for X77 were highly
reproducible in AutoDock Vina when carried out in 5 independent runs (standard error: 0.06 kcal/mol).
Therefore, we used AutoDock Vina for all our blind and focused docking, with exhaustiveness set to 24.
2.3. Evaluation of ZINCPharmer Hits Using Molecular Docking
All initial 134 compounds from ZINCPharmer were subjected to blind docking against monomeric
SARS-CoV-2 Mpro. In the blind-docking round, the top-ranked (i.e., with the lowest ∆G) poses of most
compounds, except for PubChem compound ID (CID) 2754601 (Supporting Information, Table S1),
were in the active site of the protease. Out of the 134 molecules, only 15 scaffolds (Supporting
Information, Figure S2) had ∆G values comparable to or lower than that of X77 (∆G ~8.5 kcal/mol),
which we arbitrarily used as a cut-off. Those 15 molecules were then subjected to possible pose
refinement through focused docking (Figure 2). The achieved scores in the blind and focused docking
of the chosen 15 molecules were very similar regardless of grid-size differences (Supporting Information,
Table S1 and Figure 2).
Out of the 15 evaluated molecules in focused docking, the top 7 hits (Figure 3) were selected
(highlighted red in Figure 2A) on the basis of their ∆G values and the nature of interactions with
the protease, and successful blind docking against the active site of the dimeric Mpro (results
not shown). All these compounds had reproducible scores and poses in each of the 3 independent
docking runs. PubChem CID 16424631 had the lowest mean value of −9.9 kcal/mol, followed
by PubChem CIDs 17571683 and 17572009, with scores of −9.4 and −9.2 kcal/mol, respectively.
All hits are commercially available (Supporting Information, Table S2). While we tried to ensure
that there was diversity in the chosen set of scaffolds, PubChem CIDs 17571683 and 17572009
have very similar scaffolds, which led to similar AutoDock Vina scores. Upon visual inspection,
none of our top seven selected scaffolds was deemed comparable to any of the known inhibitors of
SARS-CoV-1/SARS-CoV-2 Mpro listed in the IUPHAR/BPS Guide to Pharmacology [28] and PostEra’s
COVID Moonshot page (https://covid.postera.ai/covid/structures) [29]. Overall, 31 unique scaffolds
were compared (Supporting Information, Table S3). When searching the ChEMBL database [30],
only PubChem CID 5281696 was flagged up as a 100% match with sciadopitysin, while the other
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6 molecules as queries produced no hits. Interestingly, sciadopitysin (PubChem CID 5281696) was
previously found to inhibit SARS-CoV-1 Mpro in a fluorescence-resonance energy-transfer (FRET) assay
(38.4 ± 0.2 µM) [31], demonstrating the predictive power of our approach.
Molecules 2020, 25, x 4 of 14 
 
 
Figure 2. Overview of AutoDock Vina scores obtained in focused docking and protein–ligand 
interactions of a selection of compounds. Compound labels are PubChem compound IDs (CIDs) with 
available names shown on the bar. (A) Analysis of protein–ligand interactions using Protein–Ligand 
Interaction Profiler (PLIP) and LigPlot+ focusing on similar interactions as X77 original cocrystallised 
control and interactions with catalytic dyad; (B) AutoDock Vina mean predicted energy of interaction 
scores from three independent runs; (C) frequency of compounds interacting with residues in PLIP 
and LigPlot+. Catalytic residues, histidine 41 (His41), and cysteine 145 (Cys145) are underlined. 
 
Figure 3. Two-dimensional structures of top seven selected compounds labelled with PubChem CIDs. 
Figure 2. Overview of AutoDock Vina scores obtained in focused docking and protein–ligand
interactions of a selection of compounds. Compound labels are PubChem compound IDs (CIDs) with
available names shown on the bar. (A) Analysis of protein–ligand interactions using Protein–Ligand
Interaction Profiler (PLIP) and LigPlot+ focusing on similar interactions as X77 original cocrystallised
control and interactions with catalytic dyad; (B) AutoDock Vina mean predicted energy of interaction
scores from three independent runs; (C) frequency of compounds interacting with residues in PLIP
and LigPlot+. Catalytic residues, histidine 41 (His41), and cysteine 145 (Cys145) are underlined.
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2.4. Protein–Ligand Interactions
All seven chosen molecules seemed to span multiple subpockets within the active site of
SARS-CoV-2 Mpro (Figure 4). The poses were also analysed for interactions with the Mpro in
Protein–Ligand Interaction Profiler (PLIP; Figures 5 and 6) and LigPlot+ (Supporting Information,
Figures S3 and S4), and are compared in Figure 2A. PLIP and LigPlot+ are based on different algorithms,
with PLIP predicting interactions in 3D and LigPlot+ in 2D. Therefore, the two programmes are not
directly comparable, but together they serve the purpose of providing a more holistic picture on
potential protein–ligand interactions. In both PLIP and LigPlot+, most compounds interacted with at
least one of the two catalytic residues (His41 and Cys145; Figure 2A) via hydrophobic interactions
or hydrogen bonds. The known inhibitor, X77, also only showed interaction with His41 in PLIP
(Figure 5), while both His41 and Cys145 were shown to interact in LigPlot+ (Supporting Information,
Figure S3). Generally, there appeared to be more predicted interactions in LigPlot+, which were
primarily hydrophobic, whereas PLIP seemed to highlight more hydrogen bonds, fewer hydrophobic
interactions, and overall fewer interactions (Figure 6 and Supporting Information, Figure S4). Therefore,
it is not surprising that fewer compounds were shown to interact with both catalytic residues in PLIP,
while most compounds did in the predictions from LigPlot+.
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Besides comparing the predicted interactions with the catalytic dyad between the compounds,
we compared interacting residues with those known for X77 (Figure 2A). None of the compounds had
the same predicted interactions as the X77 control (Figure 5 and Supporting Information, Figure S3),
but PubChem CIDs 5074221, 5281696 (sciadopitysin), 7173849, and 7052206 showed the greatest
similarity to X77 in PLIP and LigPlot+-based analyses (Figure 2A).
Of the 15 molecules that were chosen for focused docking, more than 76% in their top-ranked
docked poses interacted with His41, Glu166, and Gln189 (Figures 2C and 6). Such interactions were also
observed for X77 in the original crystallographically obtained pose (Figures 2C and 5, and Supporting
Information, Figure S3).
2.5. Ligand Properties
The predicted properties of the ligands are presented in Table 1. Four of the seven compounds
comply with Lipinski’s rule of five (PubChem CIDs: 17571683, 17572009, 1601667, and 50742221). One of
the compounds (PubChem CID: 50742221) had an alert for having a pan-assay interference compound
(PAINS) feature. Six of the compounds were predicted to contain toxic groups, (PubChem CIDs:
16424631, 17571683, 17572009, 1601667, 50742221, and 7173849), also known as Brenk alerts [32].
Three compounds were predicted to have moderate solubility (PubChem CIDs: 17571683, 17572009,
1601667), while the others were predicted to have poor solubility. Most of the compounds were predicted
to theoretically have good oral pharmacokinetics (high gastrointestinal absorption), except for PubChem
CIDs 5281696 and 7173849.
Table 1. SwissADME results of top seven selected compounds labelled with PubChem CIDs.
PubChem CID
(also Known as) Druglikeness Structural Alerts Pharmacokinetics
4 Water Solubility 5
16424631 Meets Lipinski’s rules,except MLOGP 1 > 4.15






17571683 Meets Lipinski’s rules PAINS: 0 alerts; Brenk: 1alert-coumarin High GI absorption
Moderately soluble;
iLOGP: 3.83
17572009 Meets Lipinski’s rules PAINS: 0 alerts; Brenk: 1alert-coumarin High GI absorption
Moderately soluble;
iLOGP: 4.40





Meets Lipinski’s rules except
MW > 500 PAINS: 0 alerts; Brenk: 0 alerts Low GI absorption
Poorly soluble;
iLOGP: 4.65
50742221 Meets Lipinski’s rules
PAINS: 1 alert-imine phenol;
Brenk: 3 alerts-imine, nitro group,
oxygen–nitrogen single bond
High GI absorption Poorly soluble;iLOGP: 3.15
7173849
Meets Lipinski’s rules except
MW > 500 and hydrogen
bond acceptors > 10
PAINS: 0 alerts; Brenk: 2
alerts-more than 2 esters,
phthalimide
Low GI absorption Moderately soluble;iLOGP: 2.85
1 Moriguchi octanol–water partition coefficient [33], 2 pan-assay interference compounds [34], 3 Brenk alerts to toxic
groups [32], 4 according to BOILED egg method [35], 5 predicted using LogS (Ali) [36], 6 octanol/water partition
coefficient [37].
3. Discussion
Amid the ongoing pandemic, there are currently no licensed antiviral medications to cure
COVID-19 or an approved vaccine to prevent the infection. Given this, there has been an immense
focus on identifying compounds for testing against the coronavirus’ main protease [38,39]. In silico
drug-discovery tools have been widely used to expedite this process [40,41]. Here, we designed
and implemented a unique fragment-guided pharmacophore-based in silico approach. A dual
combination of fragment-derived pharmacophore-based screening and molecular docking was used.
We presented seven novel scaffolds as potential candidates for prospective experimental validation
against the Mpro (Figure 3). We deliberately considered libraries of purchasable natural products
and their derivatives as an important source of diverse bioactive chemical scaffolds, many of which
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were utilised as chemical probes, drugs, or leads for developing modern drugs that notably include
antimicrobials [42,43]. While we have not yet found a use for any method similar to ours in identifying
novel chemotypes to test against SARS-CoV-2 Mpro, one of our top seven hits (sciadopitysin) was also
identified in a recent in silico study [44]. Interestingly, sciadopitysin was previously reported to inhibit
SARS-CoV-1 Mpro in vitro with an IC50 of 38.4 µM [31].
Previous in silico work mainly focused on identifying already approved drugs that can be
repurposed against the Mpro [45–52]. By now, this in silico approach has been widely exhausted,
and there are hundreds of hits reported in the literature. Although we acknowledge that drug
repurposing is a highly sought solution given the urgency of the pandemic, we recognise the merit
of exploring a much larger drug or leadlike chemical space for finding novel hits or leads toward
specifically designing potent antiviral agents against the novel coronavirus’ Mpro.
The identification of diverse scaffolds with inhibitory activity against the Mpro can facilitate the
drug-discovery process through scaffold hopping [53,54]. The greater the number of diverse scaffolds
tested against the Mpro is, the more functional data are available to delineate which key ligand groups
and protein amino acids play an important role in ligand–protein binding, and the inhibition of protein
activity [53,55]. For example, the COVID Moonshot Initiative [29] has invited scientists from around
the world to submit structures for in vitro testing to use structure–activity relationships and identify
the most potent scaffolds. For any drug-discovery venture, several distinct chemical classes are always
needed with which to begin, since there is often attrition in the number of scaffolds as they move from
various stages of preclinical development. We confirmed the scaffold novelty of our set by taking two
approaches: the visual assessment of known SARS-CoV-1/SARS-CoV-2 Mpro inhibitors, and a more
objective automated search of the ChEMBL database and the PostEra COVID Moonshot platform.
Inhibitory fragments used in this work were previously shown to target multiple subpockets within
the active Mpro site [20]. Therefore, their pharmacophore features were valuable in identifying hits.
We used the ZINCPharmer tool, which was successfully used to discover novel inhibitors that are
active in vitro [56–59]. Our integrative approach of combining the predictions of two ligand-protein
interaction predictors (PLIP [60] and LigPlot+ [61]) also allowed for us to assess whether the predicted
binding affinity scores for the compounds were reflecting key inhibitory residues in the active site.
Most tested compounds were predicted to interact with at least one of the catalytic residues in
PLIP and LigPlot+, and had similar interactions to the chosen X77 control ligand. LigPlot+ assesses
interactions in 2D, while PLIP does so in 3D, including more interactions apart from hydrogen
bonds and hydrophobic interactions (salt bridges, π–π stacking, and π–cation interactions). This may
grant PLIP greater reliability. Yoshino et al. (2020) [62] found that His41, Gly143, and Glu166 were
important residues for peptide inhibitors in molecular-dynamics simulations. Our control molecule,
X77, interacted with all three of these residues, while His41 and Glu166 were the two most common
interacting residues within our compound set (Figure 2C).
Our study highlights a novel set of seven commercially available compounds with favourable
predicted free energy of interactions and likely poses against SARS-CoV-2 Mpro. We propose that these
molecules represent potential candidates for prospective in vitro validation against SARS-CoV-2 Mpro.
While our study is solely based on in silico analyses, multiple examples show that AutoDock Vina
scores are correlated with experimental data [63–66]. If proven to bind to and inhibit the protease,
our scaffolds can be subjected to further optimisation through the iterative use of medicinal chemistry,
and further testing against the Mpro to evaluate their effects on its activity. This could significantly
improve their potency, safety, and stability. We also present an in silico pipeline that can be applied to
screen a much larger drug or leadlike chemical space, and this could lead to the identification of more
novel scaffolds to be tested against SARS-CoV-2 Mpro.
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4. Materials and Methods
4.1. Virtual Screening with Fragment-Based Pharmacophores
The 3D structures of 17 active fragments (Supporting Information, Figure S1) that were
cocrystallised with SARS-CoV-2 Mpro as noncovalent binders to its active site in Diamond Light
Source Mpro XChem Screen [20] were obtained from the PDB. Each fragment was entered as a query
into ZINCPharmer [21] to screen a subset of the ZINC database comprising natural products and
their derivatives [67] in order to identify molecules with similar pharmacophore features (Figure 7).
The pharmacophore properties of the fragments were largely kept as the original. However, to maximise
the chance of finding more hits, some pharmacophore features deemed nonessential for interacting
with the Mpro active site were removed.Molecules 2020, 25, x 9 of 14 
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4.2. Protein-Structure Preparation
The 3D structure of SARS-CoV-2 Mpro with cocrystallised noncovalent inhibitor X77 was obtained
from PDB (PDB ID: 6W63) [19]. Preparations of the protein for docking were made in ICM-Pro 3.8 [68],
including the removal f li and and water molecules, and the addition of hydrogens.
4.3. Molecular Docking
Before performing any docking with the ZINCPharmer-derived hits, validation docking was
performed with known inhibitor X77. The latter was blindly docked [69,70] against the entire
SARS-CoV-2 Mpro structure using AutoDock Vi a [22]. The highest-ranked (i.e., with the lowest
predicted free energy of interaction, ∆G, kcal/mol) docked pose of X77 was superimposed on its
original pose present in the crystal structure, and the RMSD was calculated in DockRMSD v1.1 [71].
The average ∆G value for X77 was calculated out of 5 independent docking runs. The exhaustiveness
value for docking was set t 24.
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In addition to AutoDock Vina, three other docking programs were initially tested for the blind
docking of the X77 control. These programmes included AutoDock 4.2 (AD 4.2) [23,24], GOLD suite
version 5.8.0 (CCDC, Cambridge, UK) [26], and the SwissDock server (www.swissdock.ch) [25].
For AD 4.2-based blind docking, the Lamarckian genetic algorithm was used with a grid box that
had the same dimensions as those for blind docking with AutoDock Vina. Additionally, pseudoblind
docking was performed in GOLD with a larger grid box of 10 Å (instead of the default 6 Å) set
around the centre of mass of the X77 control in the active site. For SwissDock, the blind mode was
opted for [25].
All molecules derived from the ZINCPharmer-based virtual screening were initially subjected to
blind docking against the unliganded monomeric Mpro structure using AutoDock Vina. Molecules for
docking were obtained from PubChem (https://pubchem.ncbi.nlm.nih.gov) in 3D file format. Following
this unbiased docking approach, subsequent focused docking with a grid centred on the active site
of the Mpro structure was used for a subset of initial hits, the best poses of which had ∆G values
comparable to or lower than that of X77. As with blind docking, the exhaustiveness value was set to 24;
for each molecule, 3 independent docking runs were performed, and the mean predicted interaction of
binding was calculated. Hits scoring well in focused docking were also blindly docked against the
dimeric Mpro structure to elucidate hits potentially binding to the dimer interface, and only selecting
those with predicted binding to the active site.
4.4. Analysis of Protein–Ligand Interactions
Protein–ligand interactions were analysed in the Protein–Ligand Interaction Profiler (PLIP) [60],
and LigPlot+ 4.5.3 [61]. The resulting interaction profiles were compared with the interactions of
known inhibitor X77, and interaction with the catalytic dyad was particularly considered during the
selection of hits.
4.5. Scaffold Novelty
For the evaluation of scaffold novelty, the 2D structures of the chosen hits were visually
compared against all structures listed on the IUPHAR/BPS Guide to Pharmacology [28] and PostEra’s
COVID Moonshot initiative (https://covid.postera.ai/covid/structures) [29] known to be inhibitors
of SARS-CoV-1/SARS-CoV-2 Mpro. PostEra’s COVID Moonshot initiative platform and the entire
ChEMBL database (www.ebi.ac.uk/chembl) [30] were also searched to check for scaffold novelty.
Where available, bioassay results were checked on PubChem profiles to explore whether a particular
compound had previously been tested against the Mpro.
4.6. Exploring Ligand Properties
The SwissADME [32] server (www.swissadme.ch) was used to predict the pharmacokinetic and
toxicological properties of the compounds.
4.7. Figure Creation
A range of programmes were used to aid in figure creation. These included PyMOL 2.4
(https://pymol.org/2), UCSF Chimera 1.14 [72], R Studio [73], and Microsoft PowerPoint 2016. The 2D
chemical structures of ligands were drawn using MarvinSketch 20.16 (ChemAxon Ltd.) [74].
Supplementary Materials: The following are available online. Figure S1: 2D structures of 17 active fragments
from Mpro XChem Screen; Figure S2: 2D structures of tested compounds; Figure S3: X77 LigPlot+ interactions
with Mpro; Figure S4: top seven hits of LigPlot+ interactions with Mpro; Table S1: Blind docking scores for all
134 compounds; Table S2: List of vendors, IDs, and SMILES of 15 compounds from focused docking; Table S3:
list of known SARS-CoV-1/SARS-CoV-2 Mpro inhibitors.
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